Skip to main content


Swipe om te navigeren naar een ander artikel

01-01-2015 | Original Article-E-Learning | Uitgave 1/2015 Open Access

Netherlands Heart Journal 1/2015

“First experience with JenaValve™: a single-centre cohort”

Netherlands Heart Journal > Uitgave 1/2015
V. J. Nijenhuis, M. J. Swaans, V. Michiels, T. de Kroon, R. H. Heijmen, J. M. ten Berg
Belangrijke opmerkingen
All the above mentioned authors contributed equally to the writing of this document and approved the manuscript.
The questions can be answered after the article has been published in print. You have to log in to: www.​cvoi.​nl.



Since the introduction of transcatheter aortic valve implantation (TAVI), newer generation and novel devices such as the retrievable JenaValve™ have been developed. We evaluated the procedural and 6-month results of our first experience with implantation of the JenaValve™.

Methods and results

From June 2012 to December 2013, 24 consecutive patients (mean age 80 ± 7 years, 42 % male) underwent an elective transapical TAVI with the JenaValve™. Device success was 88 %. The mortality rate was 4 % at 30 days and 31 % at 6 months. TAVI reduced the mean transvalvular gradient (44.2 ± 11.1 mmHg vs. 12.3 ± 4.3 mmHg, p < 0.001) and increased the mean aortic valve area (0.8 3 ± 0.23 to 1.70 ± 0.44 cm2). A mild paravalvular leakage (PVL) occurred in 4 patients (18 %) and a moderate PVL in 1 patient (4 %). Mean New York Heart Association Functional Class improved from 2.9 ± 0.5 to 2.0 ± 0.8 at 30 days.


TAVI using the JenaValve™ prosthesis seems adequate and safe in this first experience cohort.

Onze productaanbevelingen

Netherlands Heart Journal

Het Netherlands Heart Journal wordt uitgegeven in samenwerking met de Nederlandse Vereniging voor Cardiologie en de Nederlandse Hartstichting. Het tijdschrift is Engelstalig en wordt gratis beschikbaa ...

Over dit artikel

Andere artikelen Uitgave 1/2015

Netherlands Heart Journal 1/2015 Naar de uitgave